China's biotech industry: An Asian dragon ...( Backed by a government intent on pro...),Health
Backed by a government intent on promoting innovation and fuelled by the brain gain of talented scientists and entrepreneurs returning from abroad, Chinas health biotech industry only needs a more favourable investment climate to emerge as a global force in the production of therapies and medicines both new and low-cost generics experts say in a new study.
Long considered a skillful product replicator, China today boasts of daring medical science innovation and stunning breakthroughs including the worlds first commercialized gene therapy product and the sole cholera vaccine tablet. However, Chinese firms face an uphill battle in attracting high-risk venture capital needed to sustain innovative, research-driven projects, says the study published by Nature Biotechnology.
Conducted through face to face interviews with management of 22 Chinese firms, the work is the first study of Chinas most innovative health biotechnology companies available in the public domain.
It says that despite substantial Chinese government funding to promote an innovative industry and entrepreneurs who will commercialize new health biotech products, the intense interest of potential international investors is typically muted by an uncertain financial system, rigid restrictions on the export of capital that limit the options for exiting investments and continuing doubts about the Chinese governments approach to quality control and intellectual property rights.
The Chinese biotechnology industry is like a baby dragon, which will grow quickly and soon become hard to ignore. Its no longer the case that the industrialized world has hegemony over biotechnology innovation, says co-author Peter A. Singer, MD, of the McLaughlin-Rotman Centre for Global Health (University Health Network and University of Toronto).
However, for all its blossoming as an industrial and economic superpower, China still has one foot in the closed society of the
'/>"/>
| Contact: Terry Collins terrycollins@rogers.com 416-538-8712 Program on Life Sciences, Ethics and Policy,McLaughlin-Rotman Centre for Global Health Source:Eurekalert |
Related medicine news :
1. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
2. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
3. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
4. Halozyme Therapeutics Added to Nasdaq Biotech Index
5. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
6. Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Councils Ninth Annual MASS Opportunities Investment Conference
7. Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy
8. E.D.G.E. in Leadership Study Delivers First-Ever Data on Executive Women in Pharmaceutical and Biotech Industries
9. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
10. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
11. GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |